Summary
Global Markets Direct’s, ‘Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2016’, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus faecium Infections
- The report reviews pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Vancomycin-Resistant Enterococcus faecium Infections therapeutics and enlists all their major and minor projects
- The report assesses Vancomycin-Resistant Enterococcus faecium Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus faecium Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Alchemia Limited
Alvogen Korea Co., Ltd.
Aphios Corporation
Cellceutix Corporation
Helix BioMedix, Inc.
Hsiri Therapeutics, LLC
LegoChem Biosciences, Inc
Lytix Biopharma AS
MGB Biopharma Limited
MicuRx Pharmaceuticals, Inc.
Nanotherapeutics, Inc.
NovaBay Pharmaceuticals, Inc.
NovoBiotic Pharmaceuticals, LLC
Oragenics, Inc.
Sealife PHARMA GMBH
Sentinella Pharmaceuticals, Inc.
TAXIS Pharmaceuticals, Inc.
Wockhardt Limited
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Vancomycin-Resistant Enterococcus faecium Infections Overview 10
Therapeutics Development 11
Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections - Overview 11
Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections - Comparative Analysis 12
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics under Development by Companies 13
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics under Investigation by Universities/Institutes 15
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Vancomycin-Resistant Enterococcus faecium Infections - Products under Development by Companies 18
Vancomycin-Resistant Enterococcus faecium Infections - Products under Investigation by Universities/Institutes 20
Vancomycin-Resistant Enterococcus faecium Infections - Companies Involved in Therapeutics Development 21
Alchemia Limited 21
Alvogen Korea Co., Ltd. 22
Aphios Corporation 23
Cellceutix Corporation 24
Helix BioMedix, Inc. 25
Hsiri Therapeutics, LLC 26
LegoChem Biosciences, Inc 27
Lytix Biopharma AS 28
MGB Biopharma Limited 29
MicuRx Pharmaceuticals, Inc. 30
Nanotherapeutics, Inc. 31
NovaBay Pharmaceuticals, Inc. 32
NovoBiotic Pharmaceuticals, LLC 33
Oragenics, Inc. 34
Sealife PHARMA GMBH 35
Sentinella Pharmaceuticals, Inc. 36
TAXIS Pharmaceuticals, Inc. 37
Wockhardt Limited 38
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
AM-218 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
auriclosene - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
brilacidin tetrahydrochloride - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
chrysophaentin - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
closthioamide - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Epimerox - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
HB-1345 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
HT-01 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
HT-02 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
IBN-1 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
LCB-010371 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
LCB-010699 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
LTX-109 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Marinus - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
MGBBP-3 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
MRX-I - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
MRX-IV - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
NAI-107 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
NAI-603 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
OG-253 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
ramoplanin - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
SLP-0904 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
SLP-0905 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecule to Inhibit Glycosyltransferase for Bacterial Infection - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecules for Bacterial Infections - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
SP-2078 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Teixobactin - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
WCK-4086 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Vancomycin-Resistant Enterococcus faecium Infections - Recent Pipeline Updates 88
Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects 105
Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products 106
Vancomycin-Resistant Enterococcus faecium Infections - Product Development Milestones 107
Featured News & Press Releases 107
Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I 107
Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project 107
Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140 108
Sep 12, 2012: NovaBay Pharma Announces Data From New Study Demonstrating Chemical Impact Of N-chlorotaurine And NVC-422 On Bacterial Toxins 108
May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent 109
Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I 109
Appendix 111
Methodology 111
Coverage 111
Secondary Research 111
Primary Research 111
Expert Panel Validation 111
Contact Us 111
Disclaimer 112
List of Tables
Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H1 2016 11
Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Development, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Development by Companies, H1 2016 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2016 20
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Alchemia Limited, H1 2016 21
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Alvogen Korea Co., Ltd., H1 2016 22
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Aphios Corporation, H1 2016 23
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Cellceutix Corporation, H1 2016 24
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Helix BioMedix, Inc., H1 2016 25
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Hsiri Therapeutics, LLC, H1 2016 26
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by LegoChem Biosciences, Inc, H1 2016 27
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Lytix Biopharma AS, H1 2016 28
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MGB Biopharma Limited, H1 2016 29
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H1 2016 30
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Nanotherapeutics, Inc., H1 2016 31
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H1 2016 32
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by NovoBiotic Pharmaceuticals, LLC, H1 2016 33
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Oragenics, Inc., H1 2016 34
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sealife PHARMA GMBH, H1 2016 35
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sentinella Pharmaceuticals, Inc., H1 2016 36
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by TAXIS Pharmaceuticals, Inc., H1 2016 37
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Wockhardt Limited, H1 2016 38
Assessment by Monotherapy Products, H1 2016 39
Number of Products by Stage and Target, H1 2016 41
Number of Products by Stage and Mechanism of Action, H1 2016 43
Number of Products by Stage and Route of Administration, H1 2016 45
Number of Products by Stage and Molecule Type, H1 2016 47
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics - Recent Pipeline Updates, H1 2016 88
Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, H1 2016 105
Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products, H1 2016 106
List of Figures
Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H1 2016 11
Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Products, H1 2016 17
Assessment by Monotherapy Products, H1 2016 39
Number of Products by Top 10 Targets, H1 2016 40
Number of Products by Stage and Top 10 Targets, H1 2016 40
Number of Products by Top 10 Mechanism of Actions, H1 2016 42
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 42
Number of Products by Routes of Administration, H1 2016 44
Number of Products by Stage and Routes of Administration, H1 2016 44
Number of Products by Molecule Types, H1 2016 46
Number of Products by Stage and Molecule Types, H1 2016 46
